Quantum Genomics S.A.
QNNTF
Other OTC0.10
USD
- -
- -
ISIN
FR0011648971
Return %
Stock
S&P500
1Y
- -
19.01
3Y
-97.06
65.48
5Y
-98.20
72.20
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Mathieu Bigois
- Full Time Employees
- 3
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 33 rue Marbeuf Paris France 75008
- IPO Date
- May 19, 2021
- Website
- quantum-genomics.com
- Similar Companies
- Business
- Quantum Genomics Société Anonyme (ALQGC: Euronext Growth) is a biopharmaceutical company specializing in the research, development, and commercialization of innovative therapies targeting unmet medical needs in cardiovascular diseases, particularly resistant hypertension and heart failure. The company focuses on a novel class of brain aminopeptidase A inhibitors (BAPAIs), with its lead candidate firibastat (QGC001) developed as an oral treatment for difficult-to-treat hypertension and related conditions; firibastat acts centrally in the brain to regulate blood pressure through inhibition of the renin-angiotensin system at its origin. Its pipeline historically included phase III programs such as FRESH and REFRESH for firibastat in hypertension, alongside QUORUM for heart failure, though development ceased following non-significant efficacy results in FRESH versus placebo in 2022. Founded in 2005 and headquartered at 6 rue Cambacérès, 75008 Paris, France, Quantum Genomics operates primarily in Europe with international partnerships extending to regions including the Middle East and Greece. The company targets patients with resistant hypertension, heart failure, and other cardiometabolic disorders underserved by existing therapies; it generates no significant revenue from product sales, relying instead on licensing, partnerships, and financing for R&D funding. Recent strategic changes include a September 2024 financing agreement with Akkadian Partners Fund for a 500,000 euro current account advance, which averted immediate judicial liquidation, enabled withdrawal of a prior liquidation filing, and facilitated a governance overhaul with Mathieu Bigois appointed as CEO and Chairman, alongside new directors Laurent de Narbonne and Pascal Ghoson. This funding supported exploration of complementary financing, external growth opportunities, and integration of a biotechnology product portfolio from Akkadian. However, following a cessation of payments declared on July 3, 2025, the Paris Commercial Court ordered simplified judicial liquidation on September 2, 2025, appointing Marie-Hélène Montravers as liquidator, suspending trading, and paving the way for delisting from Euronext Growth, with closure review scheduled within six months. Earlier partnerships encompassed exclusive licensing deals, such as with Faran S.A. in Greece for firibastat distribution in 2021 and Julphar for manufacturing and commercialization in Gulf regions.
Comparing TELA Bio (NASDAQ:TELA) & Quantum Genomics (OTCMKTS:QNNTF)
Quantum Genomics and its Partners Reach a New Stage of Development in Asia
Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat in Heart Failure at the European Society of Cardiology Meeting
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III REFRESH Trial of Firibastat in Difficult-to-Treat and Resistant Hypertension with Once-a-Day Formulation of Firibastat